Direkt zum Inhalt
Merck

Regulation of growth hormone secretion by (pro)renin receptor.

Scientific reports (2015-06-04)
Yuji Tani, Shozo Yamada, Naoko Inoshita, Yukio Hirata, Masayoshi Shichiri
ZUSAMMENFASSUNG

(Pro)renin receptor (PRR) has a single transmembrane domain that co-purifies with the vacuolar H(+)-ATPase (V-ATPase). In addition to its role in cellular acidification, V-ATPase has been implicated in membrane fusion and exocytosis via its Vo domain. Results from the present study show that PRR is expressed in pituitary adenoma cells and regulates growth hormone (GH) release via V-ATPase-induced cellular acidification. Positive PRR immunoreactivity was detected more often in surgically resected, growth hormone-producing adenomas (GHomas) than in nonfunctional pituitary adenomas. GHomas strongly expressing PRR showed excess GH secretion, as evidenced by distinctly high plasma GH and insulin-like growth factor-1 levels, as well as an elevated nadir GH in response to the oral glucose tolerance test. Suppression of PRR expression in rat GHoma-derived GH3 cells using PRR siRNA resulted in reduced GH secretion and significantly enhanced intracellular GH accumulation. GH3 treatment with bafilomycin A1, a V-ATPase inhibitor, also blocked GH release, indicating mediation via impaired cellular acidification of V-ATPase. PRR knockdown decreased Atp6l, a subunit of the Vo domain that destabilizes V-ATPase assembly, increased intracellular GH, and decreased GH release. To our knowledge, this is the first report demonstrating a pivotal role for PRR in a pituitary hormone release mechanism.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
2,2′-Bichinolin-4,4′-dicarbonsäure Dinatriumsalz Dihydrat, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Atp6v0c
Sigma-Aldrich
MISSION® esiRNA, targeting human ATP6V0C, RP11-20I23.1